ERBB2 and non-small cell lung carcinoma: Furthermore, to answer whether PD-L1.BB CSR-modified CAR-T cells can overcome MPE/MA-mediated inhibition, we further evaluated the cytotoxicity and proliferation activity of HER2.28ζ/PD-L1.BB CAR-T cells in MPE-supernatant from a NSCLC patient (Pt1).